Form 4: CytomX CMO Sells Shares for Tax Obligations

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, sold 21,279 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, Inc. (CTMX), reported a sale of common stock.
• The transaction involved the disposition of 21,279 shares of common stock.
• The shares were sold at a price of $6.423 per share.
• The sale occurred on March 17, 2026.
• The purpose of the sale was solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (RSUs).
• Following this transaction, Yu-Waye Chu beneficially owns 189,446 shares, which includes 149,833 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was explicitly for tax purposes related to RSU vesting, which is a routine and non-discretionary transaction for executives and does not indicate a change in sentiment towards the company's future.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are a routine and non-discretionary event in the biotechnology and pharmaceutical industries. Such transactions are common for executives receiving equity compensation and typically do not reflect a change in management's outlook on the company's prospects, nor do they signal a strategic shift, unlike open market sales for personal reasons.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes and does not reflect a change in the insider's view of the company's value.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an insider to cover tax obligations associated with the vesting of restricted stock units. It does not reflect a change in the company's fundamentals or the insider's long-term outlook, therefore, it does not warrant a change in investment recommendation.

Keywords

CytomX Therapeutics, CTMX, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Obligations, Chief Medical Officer